Laura Jean Havrilesky, MD
MD
Duke University Medical Center
Dept. of OB/GYN
2301 Erwin Road
Durham,
NC
USA
27705-4699
Biographical Sketch: Dr. Havrilesky is an Associate Professor in the Division of Gynecologic Oncology at Duke University. She has expertise in health economic modeling and comparative effectiveness. She recently co-authored an AHRQ-funded evidence report on optimal strategies for cervical screening.
Papers:
54
A personalized paradigm in the treatment of platinum-resistant ovarian cancer: a cost utility analysis of genomic-based versus cytotoxic therapy
226
Sentinel lymph node mapping in women with high risk histology endometrial cancer
273
Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy
425
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
427
Cost comparison among different genetic testing strategies in women with epithelial ovarian cancer
469
Improving NCCN guideline-adherent care for ovarian cancer: value of an intervention
Introductory Remarks
Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: results from a prospective multicenter phase 3 NRG Oncology/GOG trial
Welcoming Remarks